TRAIL, Wnt, Sonic Hedgehog, TGFβ, and miRNA Signalings Are Potential Targets for Oral Cancer Therapy

Ammad Ahmad Farooqi 1, Chih-Wen Shu 2, Hung-Wern Huang 3, Hui-Ru Wang 3, Yung-Ting Chang 4,5, Sundas Fayyaz 6, Shyng-Shiou F. Yuan 7,8, Jen-Yang Tang 9,10,11,* and Hsueh-Wei Chang 7,12,13,14,15,*

1 Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 54000, Pakistan; ammadfarooqi@rlmclahore.com
2 Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 81362, Taiwan; cwshu@vghks.gov.tw
3 Institute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan; sting@mail.nsysu.edu.tw (H.-W.H.); whr0319@gmail.com (H.-R.W.)
4 Doctoral Degree Program in Marine Biotechnology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan; poppiiy@gmail.com
5 Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei 11529, Taiwan
6 Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore 44000, Pakistan; sundas.khan23@yahoo.com
7 Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; yuanssf@ms33.hinet.net
8 Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
9 Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
10 Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan
11 Department of Radiation Oncology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 80145, Taiwan
12 Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan
13 Department of Medical Research, Kaohsiung Medical University Hospital; Kaohsiung Medical University, Kaohsiung 80708, Taiwan
14 Research Center for Natural Products & Drug Development, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
15 Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

* Correspondence: reyata@kmu.edu.tw (J.-Y.T.); changhw@kmu.edu.tw (H.-W.C.);
Tel.: +886-7-291-1101 (ext. 8105) (J.-Y.T.); +886-7-312-1101 (ext. 2691) (H.-W.C.);
Fax: +886-7-312-5339 (J.-Y.T. & H.-W.C.)

Received: 7 June 2017; Accepted: 13 July 2017; Published: 14 July 2017

Abstract: Clinical studies and cancer cell models emphasize the importance of targeting therapies for oral cancer. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is highly expressed in cancer, and is a selective killing ligand for oral cancer. Signaling proteins in the wingless-type mouse mammary tumor virus (MMTV) integration site family (Wnt), Sonic hedgehog (SHH), and transforming growth factor β (TGFβ) pathways may regulate cell proliferation, migration, and apoptosis. Accordingly, the genes encoding these signaling proteins are potential targets for oral cancer therapy. In this review, we focus on recent advances in targeting therapies for oral cancer and discuss the gene targets within TRAIL, Wnt, SHH, and TGFβ signaling for oral cancer therapies. Oncogenic microRNAs (miRNAs) and tumor suppressor miRNAs targeting the genes encoding these signaling proteins are summarized, and the interactions between Wnt, SHH, TGFβ, and miRNAs are interpreted. With suitable combination treatments, synergistic effects are expected to improve targeting therapies for oral cancer.

Int. J. Mol. Sci. 2017, 18, 1523; doi:10.3390/ijms18071523 www.mdpi.com/journal/ijms
Keywords: TRAIL; Wnt; sonic hedgehog; TGFβ; miRNA; target therapy; oral cancer

1. Introduction

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also referred to as the tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10), is an apoptosis-inducible cytokine [1]. TRAIL is highly expressed in cancer, and is a selective killing ligand for cancer therapy [2,3]. TRAIL may crosstalk to transforming growth factor β (TGFβ; TGFβ1) in disease progression and apoptosis. For example, TRAIL can upregulate TGFβ expression to induce extracellular matrix generation in fibroblasts [4]. TRAIL-induced death-inducing signaling complex (DISC) formation for apoptosis was inhibited in TGFβ-treated human breast epithelial cells [5]. Accordingly, TRAIL and TGFβ may crosstalk to regulate migration and apoptosis. Moreover, TGFβ is also reported to crosstalk to Sonic hedgehog (SHH) to increase cyclosporine-stimulated cell proliferation of human gingival fibroblasts [6], and to increase the motility and invasiveness of gastric cancer cells [7]. TGFβ, SHH, and wingless-type MMTV integration site family (Wnt) also crosstalk to regulate mesenchymal transition (EMT) [8] in tumor progression [9]. Accordingly, these signalings are potential targets for cancer therapy. Additionally, different microRNA (miRNA) profiles may have diverse distributions and functions in regulating these signalings. The following sections aim to summarize updated literature on the roles of TRAIL, TGFβ, SHH, Wnt, and miRNAs as potential targets for oral cancer therapy.

2. TRAIL-Induced Intracellular Signaling in Oral Cancer

2.1. TRAIL May Be a Selective Killing Ligand for Cancer Cells

TRAIL binds extracellularly to death receptors (DR), and then the signal transmits intracellularly to induce extrinsic apoptosis [10]. For cancer cells to be more prone for TRAIL treatment, the DRs are commonly upregulated to induce apoptosis. Earlier, it was reported that TRAIL was expressed constitutively in normal oral epithelia, but underwent progressive loss in primary and metastatic oral squamous cell carcinomas (OSCC) [11]. Tumor cells have a higher sensitivity to TRAIL treatment for apoptosis than normal cells [10]. Accordingly, TRAIL-mediated signaling has emerged as one of the most deeply studied biological phenomena, as it allows differential apoptosis, affecting cancer cells, while leaving normal cells intact. Therefore, TRAIL may serve as a selective killing ligand targeting cancer cells [11,12].

2.2. TRAIL Receptor-Inducible Agents for Targeting Therapies for Oral Cancer

Mechanistically, it has been shown that the expression of TRAIL receptors can be enhanced using natural and synthetic agents (Table 1).

For example, Smilax china L. extract (SCE) notably enhanced the protein quantity of death receptor 5 (DR5; TNFRSF10B; tumor necrosis factor receptor superfamily, member 10b) by stabilizing it [13]. Phospho–extracellular signal-regulated kinase (pERK), a kind of mitogen-activated protein kinase (MAPK), was significantly reduced in SCE-treated oral mucoepidermoid carcinoma MC3 cells. Similarly, ERK inhibitor (PD98059), in combination with SCE, increased DR5 expression [13]. β-Phenylethyl isothiocyanate (PEITC) has previously been shown to efficiently induce apoptosis and inhibit tumor growth in mice. PEITC-treated OSCC HN22 cells induced an increase in DR5 expression via p38 MAPK. As expected, SB203580, a chemical inhibitor of p38 MAPK, drastically abrogated PEITC-induced DR5 upregulation [14]. Glycosylation inhibitor 2-deoxy-D-glucose, in combination with TRAIL, synergistically induced apoptosis in oral cancer KB cells via the upregulation of DR5 [15]. Suberoylanilide hydroxamic acid (SAHA) markedly enhanced the expressions of DR4, DR5, Fas cell surface death receptor (Fas), and the Fas ligand (FasL; FASLG) in oral cancer Ca9-22 and SAS cells [16].
Table 1. Drugs and natural products that regulate the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling pathway.

| Drugs/Natural Products | Gene Expression | OSCC Cell Lines | References |
|------------------------|-----------------|-----------------|------------|
| Smilax china L. extract (SCE) | 1. enhances DR5 2. reduces pERK | MC3 | [13] |
| β-Phenylethyl isothiocyanate (PEITC) | 1. enhances DR5 | HN22 | [14] |
| 2-deoxy-D-glucose | 1. enhances DR5 when combined with TRAIL | KB | [15] |
| Suberoylanilide hydroxamic acid (SAHA) | 1. enhances DR4, DR5, Fas, and the Fas ligand | Ca9-22, SAS | [16] |
| Esculetin | 1. enhances DR5 | SAS | [17] |
| S-1 (fluoropyrimidine anti-oral cancer agent) | 1. reduces tumor growth of OSCC-xenografting mice when combined with TRAIL | HSC2-xenografting mice | [18] |

Esculetin, a natural agent, efficiently induces growth arrest in oral cancer SAS cells. Moreover, DR5 has also been found to be upregulated in esculetin-treated cancer cells that consequently resulted in the sensitization of oral cancer cells to TRAIL-induced signals [17]. S-1, a fluoropyrimidine anti-oral cancer agent, in combination with TRAIL, considerably reduced tumor growth in mice xenografted with oral cancer HSC2 cells [18]. It is noteworthy that TRAIL preferentially suppressed tumor growth in B88-bearing mice, as compared to HSC2 tumor-bearing mice [18]. In addition, evidence suggests that the constitutively active Ras mutant (RasV12) expressing OSCC cells shows an increase in DR5 expression on cell surfaces. Detailed research is needed to determine the potential of TRAIL receptor-targeting therapies for constitutively active Ras mutant-expressing oral cancers [19].

3. Wnt Signaling and Oral Cancer

Wnt denotes wingless (the Drosophila segment polarity gene) and integrated or int-1 (the vertebrate homolog) genes [20]. Two types of Wnt signaling have been proposed: a canonical Wnt pathway (β-catenin-dependent) and a non-canonical Wnt pathway (β-catenin-independent).

3.1. Canonical Wnt Pathway in Oral Cancer Cells

The canonical Wnt pathway (Wnt/β-catenin pathway) plays an important role in regulating cell proliferation, migration, and apoptosis [21] and is commonly deregulated in several types of cancer, such as colon [22,23], liver [24], stomach [25], breast [26], childhood T-cell acute lymphoblastic leukemia [27], and head and neck squamous cell carcinoma (HNSCC) [28]. For example, HNSCC has been reported to have abnormal expression in the canonical Wnt signaling pathway [28]. Wnt/β-catenin signaling inhibits cell detachment-mediated apoptosis (anoikis) in SCC1 cells, and promotes HNSCC-xenografting tumor growth in vivo [29]. The mRNA expressions of Wnt signaling are overexpressed in HNSCC tissues. Stem cell-enriched side population (SP) cells derived from HNSCC highly express Wnt/β-catenin signaling, but non-SP cells do not [30]. Moreover, Wnt/β-catenin signaling may regulate the epithelial to EMT expression in tumor development of laryngeal squamous cell carcinomas (SCC) [31].

The deregulation of Wnt signaling frequently occurs in OSCC and HNSCC cells. Its Wnt signaling is commonly downregulated by the methylation of several antagonists of the Wnt pathway such as dickkopf Wnt signaling pathway inhibitor 1 (DKKI), serine/threonine kinase 11 (STK11; LKB1), protein phosphatase 2 regulatory subunit B β (PPP2R2B), runt-related transcription factor 3 (RUNX3), secreted frizzled related protein 1 (SFRP1), SFRP2, and Wnt Inhibitory Factor 1 (WIF-1) genes. However, the degree of methylation of these antagonists of the Wnt pathway may express differentially for OSCC and HNSCC cells. For an example of OSCC cell lines, WIF-1 and SFRP2 genes are frequently
methylated, but dachshund family transcription factor 1 (DACH1) and DKK1 genes are methylated at a lower frequency. Similarly, the WIF-1 gene is frequently methylated in patients with primary oropharyngeal tumors. It is noteworthy that the WIF-1 gene methylation is correlated with shorter survival for oropharyngeal tumor patients [32]. In addition, evidence suggests that patients older than 56 years old are about five times more likely to have hypermethylation on the disheveled binding antagonist of the β catenin 2 (DACT2) promoter [33]. Surprisingly, SFRP2 mRNA is highly expressed in tumor-adjacent normal tissues, but not in tumor samples. This is further validated by cell line modeling. For example, cell proliferation is inhibited in SFRP2 overexpression of OSCC cell lines (TCA8113), and tumor growth is also reduced in mice subcutaneously inoculated with TCA8113/SFRP2 cells. Both β-catenin and glycogen synthase kinase-3 β (GSK3B; GSK-3β) are considerably enhanced in the cytoplasm and cell membrane of mice xenografted with TCA8113/SFRP2 cells [34].

The canonical Wnt pathway also regulates the migration and invasion of cancer cells. For example, galectin-3 is a prognostic marker in oral tongue carcinoma [35]. Galectin-3 overexpressing OSCC TCA8113 cells display markedly enhanced proliferation, migration and invasion [36]. Moreover, Wnt upregulation, β-catenin activation, and EMT induction are noted. Since canonical Wnt signaling may activate EMT [37], Wnt antagonists are expected to suppress EMT in cancer progression. For example, TCA8113 cells co-transfected with galectin-3 and Wnt antagonist DKK1 inhibit Wnt upregulation, β-catenin activation or EMT induction [36]. However, some Wnt antagonists sometimes display Wnt-independent functions to regulate EMT. For example, both the migration and invasion potential of DKK3-silenced OSCC cells are reduced in a Wnt-independent manner [38].

Additionally, DKK3 may play a different role in the survival of HNSCC patients compared to other types of cancer. For example, DKK3 is downregulated in various types of cancer, such as liver [39], breast [40], and prostate [41], but it is not downregulated in HNSCC cells [42]. Accordingly, downregulation of DKK3 may differ with different cancer types. Survival analysis indicates that the absence of protein expression of DKK3 results in considerably longer metastasis-free survival, disease-free survival, and overall survival of HNSCC patients [42]. Therefore, the function of Wnt antagonists in oral carcinogenesis warrants further investigation.

3.2. Non-Canonical Wnt Pathway in Oral Cancer Cells

The non-canonical Wnt pathway is independent of β-catenin and low-density lipoprotein-related protein 5/6 (LRP5/6) co-receptors, and contains two branches: the planar cell polarity (PCP) pathway, and the Wnt/Ca\(^{2+}\) pathway [20]. The non-canonical Wnt pathway is activated when Wnt binds to the Frizzled receptor and its LRP5/6 co-receptor. Other putative co-receptor candidates of the Frizzled receptor have been reported, including the neurotrophin receptor homolog 1 (NRH1) [43], receptor-like tyrosine kinase (Ryk) [44], protein tyrosine kinase 7 (PTK7) [45], and receptor tyrosine kinase-like orphan receptor 2 (ROR2) [46]. In OSCC cells, the non-canonical Wnt/Ca\(^{2+}\)/protein kinase C (PKC) pathway is activated via the Wnt family member 5A (WNT5A), enhancing migration and invasion [47]. WNT5B expression is notably higher in SAS-LM8 cells, a highly metastatic cell line derived from OSCC SAS cells. Gene silencing of WNT5B considerably inhibited the formation of filopodia-like protrusive structures and migration. Stimulation of SAS-LM8 cells with WNT5B significantly increases the formation of filopodia-like protrusions [48]. Moreover, the non-canonical Wnt/Ca\(^{2+}\) pathway can regulate Ca\(^{2+}\) release from the endoplasmic reticulum (ER) for intracellular Ca\(^{2+}\) homeostasis [20].

3.3. Wnt Pathway as the Target for Oral Cancer Therapy

Many small-molecule inhibitors used to specifically target Wnt signaling proteins, such as Frizzled, Disheveled, Porcupine, or Tankyrase, are well reviewed in terms of effective dosages, Chemical Abstracts Service (CAS) numbers, and targets [49]. However, their potential application in oral cancer therapy has not been investigated. Porcupine (PORCN) is a membrane-bound O-acyltransferase essential for palmitoylation and the secretion of Wnt ligands. LGK974, a small molecule for specific
PORCN inhibition, are shown to inhibit Wnt signaling in vitro and in vivo in HNSCC HN30 cell models [50]. Honokiol, isolated from Magnolia officinalis, reduces transcription factor 4 (TCF4) and β-catenin levels in OSCC SAS cells markedly. Consequently, the target genes of β-catenin, particularly c-Myc and cyclin D1, are also reduced [51]. Accordingly, the small-molecule inhibitors and natural products for specifically targeting Wnt signaling proteins warrant further investigation in the target therapy for oral cancer in the future.

4. SHH Signaling and Oral Cancer

SHH, a regulator of vertebrate organogenesis [52], controls the proliferation of several types of stem cells [53,54] and cancers [55–58]. Recently, several SHH-signaling proteins were also found overexpressed in OSCC patients. For example, SHH was highly expressed in OSCC and appeared in the cytoplasm of epithelial cells in immunohistochemical analyses [59]. Both SHH and GLI family zinc finger 1 (glioma-associated oncogene homolog 1; GLI1) are notably upregulated in 74 OSCC samples of immunohistochemical analyses. GLI1 overexpression is associated with clinical staging of tumor and tumor recurrence of OSCC. The survival rate of OSCC patients with low GLI1 and SHH expression is longer than those with high expression [60]. OSCC immunohistochemistry shows the overexpression of patched 1 (PチCH1), which correlates with lymphatic metastasis [61]. Overexpression of nuclear GLI-1 is linked with tumor recurrence, lymphatic metastasis and the primary tumor size of OSCC. Moreover, PチCH1 or GLI1 overexpression is an indicative marker for poor prognosis in OSCC [61]. Circumstantial immunohistochemical evidence also suggests that higher GLI2 staining in 60/136 OSCC patients correlates with poor clinical outcomes. The survival time of GLI2-expressing patients after surgical procedures is five years [62]. By quantitative real-time PCR analysis, 30 OSCC patients were analyzed for various genes of the SHH-signaling pathway. As a result, the smoothened (Smo, a kind of frizzled class receptor), GLI1, and PTCH1 genes were highly expressed in OSCC [63]. Moreover, the role of SHH in tumor development was investigated in vivo. For example, SHH knockdown by siRNA in OSCC SAS cells failed to induce tumor angiogenesis and tumor growth when it was subcutaneously xenografted in mice [64]. Accordingly, SHH-signaling proteins were overexpressed in OSCC, and have become potential targets for oral cancer therapies.

Because SHH overexpression is a poor prognosis marker for HNSCC, as mentioned above, the development of SHH inhibitors may improve the cancer therapy of HNSCC. For example, the steroidal alkaloid cyclopamine is reported to directly bind to the smoothened in the SHH pathway to inhibit SHH signaling [65]. Cyclopamine was proved to suppress HNSCC and improve the therapeutic effect through SHH signaling [66]. Recently, several synthetic SHH antagonists were developed for clinical evaluation. GDC-0449 (vismodegib), a oral clinical trial drug, demonstrated a good efficiency and safety for basal cell carcinoma and medulloblastoma [67]. Based on preclinical models against several solid tumors (such as medulloblastoma and basal-cell carcinoma) [68–70], other synthetic small-molecule SMO antagonists such as SANT1, CUR-61414 [71], HhAntag-691 [72], and GDC-0449 [68] were also reported to have better performances than cyclopamine. However, the application of these SHH inhibitors in oral cancer treatment is still rare. Therefore, these putative SHH inhibitors warrant further investigation in oral cancer therapy in the future. Moreover, several natural products-derived compounds such as curcumin, epigallocatechin-3-gallate, genistein, resveratrol, zerumbone, norcantharidin, and arsenic trioxide were shown to inhibit SHH signaling [73]. Their potential application in oral cancer treatment needs reconsideration as well.

5. TGFβ Signaling and Oral Cancer

TGFβ is a cytokine that regulates extracellular matrix (ECM) secretion from epithelial cells [74]. TGFβ is associated with carcinogenesis-associated EMT [75–77]. In the TGFβ signaling pathway, the accumulation of gene mutations and overexpression of TGFβ-signaling proteins have been reported in OSCC patients. For example, out of 97 OSCC patients, mutations of the transforming growth factor β receptor 2 (TGFBR2) gene were noted in 21% of samples, whereas novel Smad family member 3
(Smad3) mutations were identified in only three cases. Accordingly, lower levels of TGFBR2 mRNA were indicative of poor overall survival and poor disease-free survival of OSCC patients [78].

By immunohistochemical staining, Smad7 was gradually increased in mild oral epithelial dysplasia moderate to severe oral epithelial dysplasia, lesions of hyperkeratosis/epithelial hyperplasia, moderately to poorly differentiated OSCC, and well-differentiated OSCC [79]. Similarly, the upregulation of Smad7 and the downregulation of Smad3, Smad2, Smad4 and TGFβ receptor II (Tgfbr2; TβRII) in immunohistochemical staining were reported during chemically induced buccal pouch carcinogenesis [80]. By real-time quantitative RT-PCR analysis, the Smad2 negativity and Smad6 positivity were predictive of good prognoses for OSCC patients, independent of lymph nodal status, as evidenced by Cox multivariate analysis [81]. Median overall survival (mOS) was not achieved in the Smad2-negative and Smad6-positive OSCC groups of patients, but an mOS of 11.6 months was noted in a Smad2 positive/Smad6 negative subgroup [81].

Expression of E221V/N238I mutant of TGFβ receptor II (TβRII) gene-enhanced TGFβ has been reported to induce intracellular signaling in OSCC. More importantly, impaired lipid raft-dependent endocytosis of TβRII has been noted in mutant TβRII, thus highlighting the fact that considerably increased TGFβ signaling by this mutation is due to delay internalization of TβRII [82]. Inverse relationship of ADAM metallopeptidase domain 12 (ADAM12) and TGFβ3 has previously been noted by increased TGFβ3 expression in ADAM12-silenced HSC-3 cells [83].

Stimulating OSCC HSC-4 cells with TGFβ1 markedly enhanced p-SMAD2 and target genes [84]. Moreover, the zinc finger protein SNAI2 (Slug) and the integrin α3β1 were also notably increased in mRNA and protein expressions in TGFβ1-treated cells. Gene silencing of Slug by siRNA remarkably reduced TGFβ1-induced EMT and the cell migration of HSC-4 cells [84]. The role of TGFβ1 in tumor development in vivo showed that antisense TGFβ1 oligonucleotides reduced tumor growth considerably in mice xenografted with SCC9 cells [85]. Accordingly, TGFβ-signaling proteins were overexpressed in OSCC, and have become potential targets for oral cancer therapies.

6. miRNAs and Oral Cancer

miRNAs, primarily transcribed by RNA polymerase II, are a family of highly conserved non-protein-coding RNAs containing about 19–25 nucleotides [86]. One miRNA may modulate hundreds of targets, and multiple miRNAs may regulate one target gene [87]. Some miRNAs are oncogenic and some are tumor-suppressing in several types of cancer, such as lung, liver, breast, bladder, prostate, ovary, and kidney [88]. Different miRNA profiles may have diverse distributions and functions for different types of cancer. The function of these miRNAs acts by complementing the miRNA seed region with 3′ untranslated regions (3′ UTRs) or coding regions of target mRNAs [89], leading to mRNA degradation and subsequently decreasing their protein expressions. In this review, we compiled the targets of different miRNAs for potential oral cancer therapies in Table 2.

6.1. Targets of Oncogenic miRNAs for Oral Cancer Cells

Many anticancer drugs are developed by a strategy of modulating oxidative stress [90,91]. Some natural products were also reported to be anti-oral cancer cells through reactive oxygen species (ROS) modulation [92–94]. ROS may activate EMT transcription factors such as signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3) that is activated by TGFβ, Wnt, Hedgehog, and Akt (protein kinase B, PKB) [95]. Furthermore, the p53-upregulated modulator of apoptosis (PUMA; BC2 binding component 3; BBC3) may also interact with Akt. For example, anticancer drugs such as idelalisib [96] and pazopanib [97] were reported to activate PUMA in colon cancer cells by inhibiting Akt signaling. Accordingly, Akt, STAT3, and PUMA may interact with each other. In this review, we focus on the miRNAs that regulate these signaling expressions. We briefly introduce the oncogenic miRNAs targeting Akt, STAT3, and PUMA expressions for oral cancer cells as follows:
6.1.1. Akt and miR-31

Epidermal growth factor (EGF)-induced signaling is involved in the increased expression of miR-222, miR-181b and miR-31 in OSCC (HSC-3, OE CM-1 and SAS) cells [98]. The chemical inhibition of a serine/threonine-specific protein kinase Akt decreases EGF-induced miR-31 expression, while cells reconstituted with Akt re-expressed miR-31 upon EGF treatment. Importantly, Akt notably enhanced the CCAAT/enhancer binding protein (C/EBP) β (C/EBPβ; CEBPB), as evidenced by the increased expression of C/EBPβ after Akt activation in oral cancer cells. Stable overexpression of the functional isoform of C/EBPβ in OSCC cells resulted in an upregulation of miR-31. Circumstantial evidence also indicated that K14-EGFP-miR-31 transgenic mice displayed a significantly higher chemical carcinogen-mediated squamous cell tumor progression. In the squamous epithelium of transgenic mice, the expression of H2A histone family member X (H2AFX; γH2AX), a DNA double strand break marker, was notably enhanced after irradiation or treatment with chemical carcinogens. DNA repair genes, particularly Ku80 (XRCC5; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)) and PARP1 (poly (ADP-ribose) polymerase 1) were noted to be targets of miR-31 [99]. Accordingly, the Akt inhibitor may inhibit the function of oncogenic miR-31 in oral cancer therapy. Treatment with interfering oncogenic miR-31 may inhibit the oral cancer progression.

6.1.2. STAT3 and miR-21

miR-21 expression is triggered by STAT3 in oral cancer TCA8113 and TSCCA cells [100]. The chemical inhibition of STAT3 using WP1066, a small molecular inhibitor that efficiently reduced miR-21 expression and re-expression of the tissue inhibitor of metalloproteinase 3 (TIMP-3), programmed cell death 4 (PDCD4) and phosphatase and tensin homolog (PTEN), was noted. WP1066 also induced tumor regression in OSCC-xenografted mice as well [100]. Accordingly, STAT3 inhibitor may inhibit the function of oncogenic miR-21 in oral cancer therapy. Treatment with interfering oncogenic miR-21 may inhibit the oral tumor growth.

6.1.3. PUMA and miR-222

PUMA is a pro-apoptotic protein that is negatively regulated by miR-222 in oral cancer TCA8113 and UM1 cells [101]. Targeting miR-222 considerably improves PUMA expression and produces a higher apoptotic rate in cells [101]. Accordingly, PUMA activator may inhibit the function of oncogenic miR-222 in oral cancer therapy. Treatment with interfering oncogenic miR-222 may induce apoptosis to inhibit the oral carcinogenesis.

6.2. Targets of Tumor Suppressor miRNAs for Oral Cancer Cells

Several targets of tumor suppressor miRNAs have been summarized in Table 2. These targets were retrieved from the literature. Due to the complex interactions, it remains difficult to understand the relationship and crosstalk between their encoding proteins. The possible protein–protein interaction for these tumor suppressor miRNAs targets were predicted (Figure 1) using the bioinformatic tool, STRING, version 10.5 [102]. The interactions between these targets contain several closely related pathways and form a network. Although 10 functional partners were predicted (dash-lined box), we only focus on the targets of tumor suppressor miRNAs (no box). In oral cancer cells, several tumor suppressor miRNAs and their corresponding targets are summarized as follows (Sections 6.2.1–6.2.11).
Figure 1. The predicted protein–protein interaction for the tumor suppressor oncogenic microRNA (miRNA) targets in Table 2. This network was constructed using STRING version 10.5 [102]. All the protein symbols carry the official name of HUPO. Proteins encoded by tumor suppressor miRNAs targets in Table 2 do not have any boxes, i.e., ERRRA, NRP1, IGF1R, DKK2, PRKCI, EGFL7, HSPH1, HSP90AA1, WNT7B, FOXC1, GIT1, and CXCR4. Ten proteins within the dash-lined box (SUGT1, CDC37, PTGES3, STIP1, AHSA1, PARD6A, TTC28, SUGT1P3, TTC12, and TTC31) indicate the predicted functional partners connecting to the proteins encoded by tumor suppressor miRNAs targets. Only EGFL7 is unable to find the possible interacting proteins under the current version of STRING. The meanings associated with each of the colored lines are the same as mentioned in STRING, including (1) known interaction from curated databases or experimentally determined, (2) predicted interactions from gene neighborhood, gene fusion, or gene co-occurrence, and (3) others (text mining, co-expression, or protein homology). In brief, proteins with lines connecting to others indicate the existence of possible interactions.

Table 2. miRNAs and their target genes in oral cancer cells.

| miRNAs             | Target Genes | OSCC Cell Lines          | References |
|--------------------|--------------|--------------------------|------------|
| **Oncogenic miRNAs** |              |                          |            |
| miR-31             | Akt          | HSC-3, OECM-1, SAS       | [98]       |
| miR-21             | STAT3        | TCA8113, TSCCA           | [100]      |
| miR-222            | PUMA         | TCA8113, UM1             | [101]      |
| **Tumor suppressor miRNAs** |              |                          |            |
| miR-338            | NP-1         | TCA8113, SCC15           | [103]      |
| miR-639            | FOXC1        | CAL 27, SCC9             | [104]      |
| miR-219            | PRKCI        | CAL 27, SCC15            | [105]      |
| miR-410            | WNT7B        | DOK, FaDu, OC-3, OEC-M1, SCC4, SCC9, SCC15, SCC25, Tw2.6, YD-15 | [106]      |
Table 2. Cont.

| miRNAs   | Target Genes | OSCC Cell Lines | References |
|----------|--------------|-----------------|------------|
| miR-27a  | Hsp90, Hsp110| HSC-4           | [107]      |
| miR-125a | ERFa         | SCC084, SCC131  | [108]      |
| miR-126  | EGFL7        | SCC-15          | [109]      |
| miR-99a  | IGF1R        | CGHNC9, OC-3, OEC-M1, TW2.6, FaDu, KB, SCC4, SCC15, SCC9, SCC25, UT-MUC-1, YD-15, DOK, Tu183, UM5CC1, HSC3 | [110] |
| miR-491-5p| GIT1         | CGHNC9, SAS, SCC25, OEMC-1, OC-3 | [111] |
| miR-9    | CXCR4        | TCA8113, SCC9   | [112]      |
| miR-21   | DKK2         | SCC25           | [113]      |

6.2.1. Neuropilin-1 (NP-1; NRP1) and miR-338

miR-338 is frequently downregulated in oral cancer TCA8113 and SCC15 cells, and the enforced expression of miR-338 resulted in the inhibition of colony formation, migration, proliferation and invasion [103]. Neuropilin-1 (NP-1) is a target of miR-338, and enforced expression of NP-1 impaired those miR-338-exerted inhibitory effects on oral cancer cells [103]. Accordingly, NP-1 inhibitors may activate the function of tumor suppressor miR-222 in oral cancer therapy. Treatment with increasing tumor suppressor miR-338 expression may inhibit the metastasis of oral cancer cells.

6.2.2. Forkhead Box C1 (FOXC1) and miR-639

Ectopic expression of miR-639 in tongue cancer CAL 27 and SCC9 cells considerably inhibited TGFβ (TGFB1; transforming growth factor, β 1)-induced EMT [104]. However, targeting inhibition of miR-639 in tongue cancer cells promoted TGFβ-induced EMT. FOXC1 was reported as a target of miR-639, as evidenced by EMT in FOXC1 overexpressing cancer cells and the loss of TGFβ-induced EMT in FOXC1-silenced cells [104]. Accordingly, miR-639 may inhibit FOXC1 expression. FOXC1 inhibitor may suppress the EMT processes in oral cancer therapy. Treatment with increasing tumor suppressor miR-639 expression may inhibit the metastasis of oral cancer cells.

6.2.3. Protein Kinase CI (PRKCI) and miR-219

PRKCI, a known target of miR-219, is noted to enhance colony formation, migration, cell proliferation and the invasion of tongue squamous cell carcinoma (TSCC) cells. Overexpression of miR-219 in tongue cancer CAL 27 and SCC15 cells markedly inhibited carcinogenesis [105]. Accordingly, miR-219 may inhibit PRKCI expression. PRKCI inhibitor may suppress the migration and invasion processes in oral cancer therapy. Treatment with increasing tumor suppressor miR-219 expression may inhibit metastasis of oral carcinogenesis.

6.2.4. WNT7B, miR-329, and miR-410

It has recently been shown that the stable ectopic expression of WNT7B in miR-329 or miR-410 overexpressing OSCC cells restored its invasive and proliferation potential [106]. The combination of the HDAC inhibitor and the demethylation agent considerably enhanced miR-410 and miR-329 in oral cancer cells. However, betel nut alkaloids, particularly arecoline, dramatically reduced miR-410 and miR-329 [106]. Accordingly, miR-329 or miR-410 may inhibit WNT7B expression. WNT7B inhibitor may suppress the migration and invasion processes in oral cancer therapy. Treatment with increasing tumor suppressor miR-329 or miR-410 expression may inhibit metastasis of oral carcinogenesis.

6.2.5. Heat Shock Proteins (HSP) and miR-27a

Certain miRNAs were shown to enhance hyperthermia-induced cell death [114]. Oral cancer cells transfected with miR-27a mimic displayed notably improved thermal sensitivity [107]. Moreover,
it was shown that overexpression of heat shock proteins induced resistance against hyperthermia. Both Hsp90 (HSP90AA1; heat shock protein 90 kDa α (cytosolic), class A member 1) and Hsp110 (HSPH1; heat shock 105 kDa/110 kDa protein 1) were markedly reduced in miR-27a mimic-transfected oral cancer HSC-4 cells [107]. Accordingly, miR-27a may inhibit Hsp90 and Hsp110 expressions. Hsp90 and Hsp110 inhibitors may suppress the resistance against hyperthermia therapy. Treatment with increasing tumor suppressor miR-27a expression may improve the thermal sensitivity of oral cancer therapy.

6.2.6. Estrogen-Related Receptor α (ERRα; ESRRA) and miR-125a

The transcription factor ERRα is involved in the regulation of different target genes in cancer [115,116]. ERRα is a target of miR-125a and ERRα levels were drastically reduced in miR-125a-overexpressing oral cancer SCC084 and SCC131 cells [108]. Moreover, miR-125a-expressing oral cancer cells induced significant regression of tumors in xenografted mice. Accordingly, miR-125a may inhibit ERRα expression. ERRα inhibitors may suppress tumor growth. Treatment with elevated tumor suppressor miR-125a may reduce tumor growth in oral cancer therapy.

6.2.7. Epidermal Growth Factor-Like Domain 7 (EGFL7) and miR-126

miR-126 was identified within intron 7 of EGFL7 genes [117]. miR-126 overexpression inhibited EGFL7 in OSCC-15 cells remarkably. The secretion of two key regulators of angiogenesis, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), were also inhibited [109]. Accordingly, miR-126 may inhibit EGFL7 expression. EGFL7 inhibitor may suppress angiogenesis. Treatment with elevated tumor suppressor miR-126 expression may reduce angiogenesis in oral cancer therapy.

6.2.8. Insulin-Like Growth Factor I Receptor (IGF1R) and miR-99a

IGF1R is a target of miR-99a, and is frequently overexpressed in oral cancer and the IGF induced repression of miR-99a [88]. miR-99a overexpression inhibited IGF1R expression and suppressed migration and invasion in vitro in oral cancer OEC-M1 and CGHNC9 cells. Mechanistically, it has been shown that treatment of oral cancer cells with inhibitors of MAPK and PI3K impaired IGF1-induced repression of miR-99a [110]. Accordingly, miR-99a may inhibit IGF1R expression. IGF1R inhibitor may suppress the migration and invasion of oral cancer cells. Treatment with increasing tumor suppressor miR-99a expression may reduce metastasis in oral cancer therapy.

6.2.9. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) and miR-491-5p

GIT1, frequently overexpressed in oral cancer, is a target of miR-491-5p [111]. miR-491-5p overexpression resulted in declining GIT1 levels and a marked decrease in the migration and lung metastasis of OSCC cells [111]. Detailed mechanistic insights revealed that miR-491-5p overexpressed GIT1-silenced OSCC cells. This indicated a reduction in focal adhesions, and a decline in the steady-state levels of phospho-paxillin, paxillin, and phospho-focal adhesion kinase (pFAK) [111]. Moreover, EGF/EGFR-induced intracellular signaling through downstream effectors, including ERK1/2 and matrix metalloproteinases (MMP) 2/9, was also repressed in OSCC cells. Accordingly, miR-491-5p may inhibit GIT1 expression. GIT1 inhibitor may suppress the migration and focal adhesions. Treatment with increasing tumor suppressor miR-491-5p expression may reduce metastasis in oral cancer therapy.

6.2.10. C-X-C Motif Chemokine Receptor 4 (CXCR4) and miR-9

Proliferation potential was notably reduced in miR-9-overexpressing oral cancer TCA8113 and SCC9 cells with highly aggressive manners [112]. CXCR4 gene is a target of miR-9. CXCR4 is
quantitatively controlled by miR-9 and the activation of CXCR4 with its ligand, notably increasing Wnt-induced intracellular signaling [112]. Curcumin, isolated from the rhizome of Curcuma longa, induced upregulation of miR-9 in SCC9 cells. Expression levels of β-catenin, GSK-3β and phospho-GSK-3β were notably enhanced in curcumin-treated SCC9 cells [118]. Accordingly, miR-9 may inhibit CXCR4 expression. CXCR4 inhibitor may inhibit oral cancer cell proliferation. Treatment with increasing tumor suppressor miR-9 expression may display antiproliferation in oral cancer therapy.

6.2.11. DKK2 and miR-21

Dickkopf Wnt-signaling pathway inhibitor 2 (DKK2) is negatively regulated by miR-21. miR-21 silenced cells did not show significant migration in OSCC SCC25 cells [113]. miR-21 negatively regulated DKK2 and negatively promoted invasions via the Wnt/β-catenin pathway. Accordingly, miR-21 may inhibit DKK2 expression. DKK2 inhibitor may suppress the migration processes in oral cancer therapy. Treatment with increasing tumor suppressor miR-21 expression may inhibit the metastasis of oral cancer cells.

7. Interactions between TRAIL, Wnt, SHH, TGFβ, and miRNA Signaling Proteins in Cancer Cells

7.1. TRAIL-Induced Apoptosis and ER Stress

Cellular oxidative stress may cause the accumulation of protein misfolding and lead to endoplasmic reticulum (ER) stress. Several drugs and natural products have been reported to modulate the ER stress and oxidative stress in cancer therapy [119]. Detailed investigations into the relationship between ER stress and TRAIL-induced apoptosis signaling in many cancer cell lines have been reported [120–124]. ER stress may also be connected to apoptosis [125]. TRAIL and its receptor have been detected in several oral cancer cells (HSC-2, HSC-3, HSC-4, Ca9-22, and KB) [126]. After exogenous TRAIL treatment for 16 hours, KB cells were found to be the most sensitive, while the others were relatively more resistant. Accordingly, most oral cancer cells are resistant to TRAIL-induced cytotoxicity, suggesting that extra treatment in combination with TRAIL may be needed to overcome its TRAIL resistance.

In addition, the modulation of ER stress has been reported to regulate apoptosis. For example, suppression of eIF2α dephosphorylation by the salubrinal (ER stress inhibitor; a specific eIF2α phosphorylation-inducing agent) improves the TRAIL-induced apoptosis in human hepatoma HepG2 cells [127]. The ER stress inducer thapsigargin sensitizes human esophageal cancer EC109 and TE12 cells to TRAIL-induced apoptosis via AMPK activation [128]. Accordingly, the role of ER stress in TRAIL-induced apoptosis remains controversial and may depend on tissue-specific or TRAIL resistant characters. Therefore, modulation of ER stress signaling may affect the clinical efficacy of TRAIL-targeting cancer therapies. Several natural products have also been reported to induce ER stress in oral cancer cells [129–133]. Further investigation is warranted into the role TRAIL plays in these ER stress-modulating drugs and the future use of natural products for TRAIL-targeting oral cancer therapies.

7.2. miRNA and TRAIL Signaling

Several TRAIL receptor-targeting agents have been used to develop drugs in clinical trials [11]. Adenovirus-mediated TRAIL expression was developed to improve TRAIL delivery for cancer therapy. However, adenovirus delivery systems may also affect normal cells because of a lack of tumor specificity [134]. Overcoming this nonspecific targeting has emerged as an important issue for adenovirus delivery of TRAIL. A differential expression profile of miRNAs between bladder cancer and normal cells has been reported [135]. For example, expression of miR-1, miR-133 and miR-218 was downregulated in bladder cancer, but not in normal bladder mucosal tissue [134]. The recombinant adenovirus system containing TRAIL and miRNA response elements (MREs) of miR-1, miR-133 and miR-218 was constructed and was shown to be bladder cancer specific in regulating TRAIL expression.
in vitro and in vivo [134]. Similarly, tumor-targeting TRAIL expression by miRNA to inhibit tumor growth or induce apoptosis was also reported in melanoma [136], prostate [137], breast [138], lung [139], and ovarian [140] cancer cells by different miRNAs.

However, some miRNAs are sensitive to TRAIL-induced apoptosis of certain types of cancer cells, but some miRNAs are resistant to them [87,141–143]. For example, miR-29 (liver cancer), miR-130a (liver cancer), miR-212 (liver cancer), and miR-185 (breast and kidney cancers) are sensitive to TRAIL-induced apoptosis in these cancer cells, whereas miR-25 (liver cancer), miR-222 (liver and lung cancers), and miR-221 (lung, liver, and bladder cancers) are resistant to TRAIL-induced apoptosis [142].

Mechanistically, some miRNAs targeting the TRAIL signaling proteins were reported to modulate TRAIL resistance in cancer cells. miRNAs have been reported to regulate apoptosis in antiapoptic or proapoptotic effects through DR signaling [144]. When looking at the example of the antiapoptic effect, miR-25 targets DR4 and the hedgehog signaling may upregulate miR-25 expression for apoptosis resistance to TRAIL-induced cholangiocarcinoma [145]. Here, miR135a-3p may upregulate DR5 expression to sensitize TRAIL-induced apoptosis in tanshinone I-treated prostate cancer cells [146]. Therefore, the identification of miRNAs involving the modulation of resistance to TRAIL-induced apoptosis in oral cancer cells warrants further investigation.

7.3. Other Complex Crosstalk

TGFβ may rapidly induce expression of Kruppel-like transcription factors GLI2 and GLI1 [147], which function as Hedgehog effector molecules [148]. Accordingly, there is crosstalk between TGFβ and hedgehog signaling in cancer. Moreover, a link between EMT and GLI-mediated regulation was reported [149]. Similarly, crosstalk between TGFβ, SHH, and Wnt [8] regulates EMT in carcinogenesis and diseases in general [9]. GLI2, GLI1, TGFβ, SHH, and Wnt show rather complex crosstalk.

In addition, miRNAs also target and regulate TGFβ, SHH, and Wnt gene expressions [150]. For example, several miRNAs targeting TGFβ signaling in breast cancer metastasis [151] and in the inflammatory microenvironment of cancer are well reviewed [152]. Several miRNAs with oncogenic or tumor suppressive functions are known to interact with Wnt-signalling pathways in carcinogenesis [153–155] and disease [156]. miRNAs also interact with hedgehog signaling in disease [157]. However, these interactions remain unclear in oral carcinogenesis and therapy. Accordingly, the interactions between TRAIL, Wnt, SHH, TGFβ, and miRNA signaling proteins in oral cancer therapy warrant further investigation.

8. Conclusions

Data obtained from cancer cell lines and clinical studies have considerably improved our understanding of the potential for targeting therapies in oral cancer treatment. TRAIL is a selective killing ligand for cancer, and several TRAIL receptor agents have been developed for use in OSCC. Wnt, SHH, and TGFβ pathway signaling proteins are also suitable targets for oral cancer therapy. Oncogenic miRNAs and tumor suppressor miRNAs with specific targets display diverse functions in oral cancer therapy through regulating carcinogenesis, migration, and invasion in vitro and in vivo. Moreover, the interactions between TRAIL, Wnt, SHH, TGFβ, and miRNAs are complex in regulating carcinogenesis. Synergistic effects from the combination of treatments may improve the targeting therapies for oral cancer.

Acknowledgments: This work was partly supported by funds of the Ministry of Science and Technology (MOST 104-2320-B-037-013-MY3 and MOST 105-2314-B-037-036), the Chimei-KMU jointed project (106CM-KMU-05), the National Sun Yat-sen University-KMU Joint Research Project (#NSYSUKMU 106-P001), the Kaohsiung Medical University Hospital (KMUH1105-5R61), and the Health and welfare surcharge of tobacco products, the Ministry of Health and Welfare, Taiwan, Republic of China (MOHW106-TDU-B-212-144007). The authors thank Hans-Uwe Dahms and Paula Bejar for English editing.
Author Contributions: Ammad Ahmad Farooqi, Jen-Yang Tang, and Hsueh-Wei Chang conceived the concept for this paper. Hui-Ru Wang, Yung-Ting Chang, and Sundas Fayyaz contributed on literature collection and analysis. Chih-Wen Shu, Shyng-Shiou F. Yuan, and Hurng-Wern Huang discussed and reorganized the literature information into different sections. Ammad Ahmad Farooqi drafted the manuscript. Jen-Yang Tang and Hsueh-Wei Chang discussed and revised the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| TRAIL        | Tumor necrosis factor-related apoptosis-inducing ligand |
| Wnt          | Wingless type MMTV integration site family |
| SHH          | Sonic hedgehog |
| TGFβ         | Transforming growth factor β |
| DR           | Death receptors |
| OSCC         | Oral squamous cell carcinomas |
| ERK          | Extracellular signal regulated kinase |
| MAPK         | Mitogen-activated protein kinase |
| HNSCC        | Head and neck squamous cell carcinomas |
| EMT          | Epithelial to mesenchymal transition |
| ECM          | Extracellular matrix |
| ER stress    | Endoplasmic reticulum stress |

References

1. Song, K.; Chen, Y.; Goke, R.; Wilmen, A.; Seidel, C.; Goke, A.; Hilliard, B.; Chen, Y. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. *J. Exp. Med.* 2000, 191, 1095–1104. [CrossRef] [PubMed]
2. Merino, D.; Lalaoui, N.; Morizot, A.; Solary, E.; Micheau, O. TRAIL in cancer therapy: Present and future challenges. *Expert Opin. Ther. Targets* 2007, 11, 1299–1314. [CrossRef] [PubMed]
3. Suzuki-Karasaki, Y.; Suzuki-Karasaki, M.; Uchida, M.; Ochiai, T. Depolarization controls TRAIL-sensitization and tumor-selective killing of cancer cells: Crosstalk with ROS. *Front. Oncol.* 2014, 4, 128. [CrossRef] [PubMed]
4. Yurovsky, V.V. Molecular cross-talk between the TRAIL and TGF-β pathways in human lung fibroblasts. *Arthritis Res. Ther.* 2003, 5, 64. [CrossRef]
5. Cano-Gonzalez, A.; Lopez-Rivas, A. Opposing roles of TGF-β and EGF in the regulation of TRAIL-induced apoptosis in human breast epithelial cells. *Biochim. Biophys. Acta* 2016, 1863, 2104–2114. [CrossRef] [PubMed]
6. Chung, Y.; Fu, E. Crosstalk between Shh and TGF-β signaling in cyclosporine-enhanced cell proliferation in human gingival fibroblasts. *PLoS ONE* 2013, 8, e70128. [CrossRef] [PubMed]
7. Yoo, Y.A.; Kang, M.H.; Kim, J.S.; Oh, S.C. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-β-mediated activation of the ALK5-Smad 3 pathway. *Carcinogenesis* 2008, 29, 480–490. [CrossRef] [PubMed]
8. Zhang, J.; Tian, X.J.; Xing, J. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. *J. Clin. Med.* 2016, 5, 41. [CrossRef] [PubMed]
9. Castellone, M.D.; Laukkanen, M.O. TGF-β1, WNT, and SHH signaling in tumor progression and in fibrotic diseases. *Front. Biosci.* 2017, 9, 31–45.
10. Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. *Nat. Rev. Cancer* 2008, 8, 782–798. [CrossRef] [PubMed]
11. Dimberg, L.Y.; Anderson, C.K.; Camidge, R.; Behbakht, K.; Thorburn, A.; Ford, H.L. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutic. *Oncogene* 2013, 32, 1341–1350. [CrossRef] [PubMed]
12. Wu, G.S. TRAIL as a target in anti-cancer therapy. *Cancer Lett.* 2009, 285, 1–5. [CrossRef] [PubMed]
13. Yu, H.J.; Shin, J.A.; Lee, S.O.; Kwon, K.H.; Cho, S.D. Extracellular signalregulated kinase inhibition is required for methanol extract of *Smilax china* L. induced apoptosis through death receptor 5 in human oral mucoepidermoid carcinoma cells. *Mol. Med. Rep.* 2014, 9, 663–668. [PubMed]
14. Huong, L.D.; Shin, J.A.; Choi, E.S.; Cho, N.P.; Kim, H.M.; Leem, D.H.; Cho, S.D. β-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38. Oral Dis. 2012, 18, 513–519. [CrossRef] [PubMed]

15. Xu, J.; Huang, Y.; Li, Y.; Pu, L.; Xia, F.; Jiang, C.; Liu, H.; Jiang, Z. Glycosylation inhibitor 2-deoxy-D-glucose sensitizes oral cancer cells to TRAIL-induced apoptosis. Nan Fang Yi Ke Da Xue Xue Bao 2013, 33, 524–527. [PubMed]

16. Yeh, C.C.; Deng, Y.T.; Sha, D.Y.; Hsiao, M.; Kuo, M.Y. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther. 2009, 8, 2718–2725. [CrossRef] [PubMed]

17. Kok, S.H.; Yeh, C.C.; Chen, M.L.; Kuo, M.Y. Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral Oncol. 2009, 45, 1067–1072. [CrossRef] [PubMed]

18. Itashiki, Y.; Harada, K.; Ferdous, T.; Yoshida, H. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Anticancer Res. 2007, 27, 2365–2375. [PubMed]

19. Chen, J.J.; Mikelis, C.M.; Zhang, Y.; Gutkind, J.S.; Zhang, B. TRAIL induces apoptosis in oral squamous carcinoma cells: A crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. Oncotarget 2013, 4, 206–217. [CrossRef] [PubMed]

20. Comi, Y.; Habas, R. Wnt signal transduction pathways. Organogenesis 2008, 4, 68–75. [CrossRef] [PubMed]

21. Komiya, Y.; Habas, R. Wnt signaling in stem cells and cancer. Nature 2005, 434, 843–850. [CrossRef] [PubMed]

22. Schneikert, J.; Behrens, J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007, 56, 417–425. [CrossRef] [PubMed]

23. Novellasdemunt, L.; Antas, P.; Li, V.S. Targeting Wnt signaling in colorectal cancer. A review in the theme: Cell signaling: Proteins, pathways and mechanisms. Am. J. Physiol. Cell Physiol. 2015, 309, CS11–CS21. [CrossRef] [PubMed]

24. Waisberg, J.; Saba, G.T. Wnt-/β-catenin pathway signaling in human hepatocellular carcinoma. World J. Hepatol. 2015, 7, 2631–2635. [CrossRef] [PubMed]

25. Chiurillo, M.A. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J. Exp. Med. 2015, 5, 84–102. [CrossRef] [PubMed]

26. Pohl, S.G.; Brook, N.; Agostino, M.; Arfuso, F.; Kumar, A.P.; Dharmarajan, A. Wnt signaling in triple-negative breast cancer. Oncogenesis 2017, 6, e310. [CrossRef] [PubMed]

27. Ng, O.H.; Erbilgin, Y.; Firtina, S.; Celkan, T.; Karakas, Z.; Aydogan, G.; Turkkan, E.; Yıldırım, Y.; Timur, C.; Zengin, E.; et al. Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia. Blood Cancer J. 2014, 4, e192. [CrossRef] [PubMed]

28. Molinolo, A.A.; Amornphimoltham, P.; Squarize, C.H.; Castilho, R.M.; Patel, V.; Gutkind, J.S. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009, 45, 324–334. [CrossRef] [PubMed]

29. Yang, F.; Zeng, Q.; Yu, G.; Li, S.; Wang, C.Y. Wnt/β-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal. 2006, 18, 679–687. [CrossRef] [PubMed]

30. Song, J.; Chang, I.; Chen, Z.; Kang, M.; Wang, C.Y. Characterization of side populations in HNSCC: Highly invasive, chemoresistant and abnormal Wnt signaling. PLoS ONE 2010, 5, e11456. [CrossRef] [PubMed]

31. Psyrri, A.; Kotoula, V.; Fountzilas, E.; Alexopoulou, Z.; Bobos, M.; Televantou, D.; Karayannopoulou, G.; Krikelis, D.; Markou, K.; Karasmanis, I.; et al. Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. Oral. Oncol. 2014, 50, 298–305. [CrossRef] [PubMed]

32. Paluszczak, J.; Sarbak, J.; Kostrzewska-Poczekaj, M.; Kiwerska, K.; Jarmuz-Szymczak, M.; Grenman, R.; Mielcarek-Kuchta, D.; Baer-Dubowska, W. The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival. Cancer Biomark. 2015, 15, 11–17. [CrossRef] [PubMed]

33. Xiao, C.; Wang, L.; Zhu, L.; Zhang, C.; Zhou, J. Secreted frizzled-related protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma. Mol. Med. Rep. 2014, 10, 2293–2298. [PubMed]
35. Honjo, Y.; Inohara, H.; Akahani, S.; Yoshii, T.; Takenaka, Y.; Yoshida, J.; Hattori, K.; Tomiyama, Y.; Raz, A.; Kubo, T. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin. Cancer Res. 2000, 6, 4635–4640. [PubMed]
36. Wang, L.P.; Chen, S.W.; Zhuang, S.M.; Li, H.; Song, M. Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β-catenin-dependent pathway. Pathol. Oncol. Res. 2013, 19, 461–474. [CrossRef] [PubMed]
37. Chen, H.C.; Zhu, Y.T.; Chen, S.Y.; Tseng, S.C. Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab. Investig. 2012, 92, 676–687. [CrossRef] [PubMed]
38. Katase, N.; Lefeuvre, M.; Tsujigiwa, H.; Fujii, M.; Ito, S.; Tamamura, R.; Buery, R.R.; Gunduz, M.; Nagatsuka, H. Knockdown of Dkk-3 decreases cancer cell migration and invasion independently of the Wnt pathways in oral squamous cell carcinomaderived cells. Oncol. Rep. 2013, 29, 1349–1355. [PubMed]
39. Yang, B.; Du, Z.; Gao, Y.T.; Lou, C.; Zhang, S.G.; Bai, T.; Wang, Y.J.; Song, W.Q. Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J. Gastroenterol. 2010, 16, 755–763. [CrossRef] [PubMed]
40. Veeck, J.; Wild, P.J.; Fuchs, T.; Schuffler, P.J.; Hartmann, A.; Knuchel, R.; Dahl, E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009, 9, 217. [PubMed]
41. Zenzmaier, C.; Untergasser, G.; Hermann, M.; Dirnhofer, S.; Sampson, N.; Berger, P. Dysregulation of Dkk-3 expression in benign and malignant prostate tissue. Prostate 2008, 68, 540–547. [CrossRef] [PubMed]
42. Katase, N.; Lefeuvre, M.; Gunduz, M.; Gunduz, E.; Beder, L.B.; Grenman, R.; Fuji, M.; Tamamura, R.; Tsujigiwa, H.; Nagatsuka, H. Absence of Dickkopf (Dkk)-3 protein expression is correlated with longer disease-free survival and lower incidence of metastasis in head and neck squamous cell carcinoma. Oncol. Lett. 2012, 3, 273–280. [CrossRef] [PubMed]
43. Sasai, N.; Nakazawa, Y.; Haraguchi, T.; Sasai, Y. The neurotrophin-receptor-related protein NRH1 is essential for convergent extension movements. Nat. Cell Biol. 2004, 6, 741–748. [CrossRef] [PubMed]
44. Lu, W.; Yamamoto, V.; Ortega, B.; Baltimore, D. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 2004, 119, 97–108. [CrossRef] [PubMed]
45. Lu, X.; Borchers, A.G.; Jolicoeur, C.; Rayburn, H.; Baker, J.C.; Tessier-Lavigne, M. PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates. Nature 2004, 430, 93–98. [CrossRef] [PubMed]
46. Nishita, M.; Yoo, S.K.; Nomachi, A.; Kani, S.; Sougawa, N.; Ohta, Y.; Takada, S.; Kikuchi, A.; Minami, Y. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J. Cell Biol. 2006, 175, 555–562. [CrossRef] [PubMed]
47. Prgomet, Z.; Axelsson, L.; Lindberg, P.; Andersson, T. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression. J. Oral Pathol. Med. 2015, 44, 776–784. [CrossRef] [PubMed]
48. Takeshita, A.; Iwai, S.; Morita, Y.; Niki-Yonekawa, A.; Hamada, M.; Yura, Y. Wnt5b promotes the cell motility essential for metastasis of oral squamous cell carcinoma through active Cdc42 and RhoA. Int. J. Oncol. 2014, 44, 59–68. [PubMed]
49. Tran, F.H.; Zheng, J.J. Modulating the wnt signaling pathway with small molecules. Protein Sci. 2017, 26, 650–661. [CrossRef] [PubMed]
50. Liu, J.; Pan, S.; Hsieh, M.H.; Ng, N.; Sun, F.; Wang, T.; Kasibhatla, S.; Schuller, A.G.; Li, A.G.; Cheng, D.; et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA 2013, 110, 20224–20229. [CrossRef] [PubMed]
51. Yao, C.J.; Lai, G.M.; Yeh, C.T.; Lai, M.T.; Shih, P.H.; Chao, W.J.; Whang-Peng, J.; Chuang, S.E.; Lai, T.Y. Honokiol eliminates human oral cancer stem-like cells accompanied with suppression of Wnt/β-catenin signaling and apoptosis induction. Evid. Based Complement. Altern. Med. 2013, 2013, 146136. [CrossRef] [PubMed]
52. Bain, V.E.; Gordon, J.; O’Neill, J.D.; Ramos, I.; Richie, E.R.; Manley, N.R. Tissue-specific roles for sonic hedgehog signaling in establishing thymus and parathyroid organ fate. Development 2016, 143, 4027–4037. [CrossRef] [PubMed]
53. Strzyz, P. Adult stem cells: Hair stem cells born without a home. Nat. Rev. Mol. Cell Biol. 2016, 17, 133. [CrossRef] [PubMed]
54. Faigle, R.; Song, H. Signaling mechanisms regulating adult neural stem cells and neurogenesis. *Biochim. Biophys. Acta* 2013, 1830, 2435–2448. [CrossRef] [PubMed]

55. Rimkus, T.K.; Carpenter, R.L.; Qasem, S.; Chan, M.; Lo, H.W. Targeting the sonic hedgehog signaling pathway: Review of smoothened and GLI inhibitors. *Cancers* 2016, 8, 22. [CrossRef] [PubMed]

56. Rubin, L.L.; de Sauvage, F.J. Targeting the Hedgehog pathway in cancer. *Nat. Rev. Drug Discov.* 2006, 5, 1026–1033. [CrossRef] [PubMed]

57. Jiang, W.G.; Ye, L.; Ruge, F.; Sun, P.H.; Sanders, A.J.; Ji, K.; Lane, J.; Zhang, L.; Satherley, L.; Weeks, H.P.; et al. Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth. *Anticancer Res.* 2015, 35, 1321–1331. [PubMed]

58. Noman, A.S.; Uddin, M.; Rahman, M.Z.; Nayeem, M.J.; Alam, S.S.; Khatun, Z.; Wahiduzzaman, M.; Sultana, A.; Rahman, M.L.; Ali, M.Y.; et al. Overexpression of sonic hedgehog in the triple negative breast cancer: Clinicopathological characteristics of high burden breast cancer patients from Bangladesh. *Sci. Rep.* 2016, 6, 18830. [CrossRef] [PubMed]

59. Srinath, S.; Iyengar, A.R.; Mysorekar, V. Sonic hedgehog in oral squamous cell carcinoma: An immunohistochemical study. *J. Oral Maxillofac. Pathol.* 2016, 20, 377–383. [CrossRef] [PubMed]

60. Fan, H.X.; Wang, S.; Zhao, H.; Liu, N.; Chen, D.; Sun, M.; Zheng, J.H. Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression. *Med. Oncol.* 2014, 31, 41. [CrossRef] [PubMed]

61. Wang, Y.F.; Chang, C.J.; Lin, C.P.; Chang, S.Y.; Chu, P.Y.; Tai, S.K.; Li, W.Y.; Chao, K.S.; Chen, Y.J. Expression of hedgehog signaling molecules as a prognostic indicator of oral squamous cell carcinoma. *Head Neck* 2012, 34, 1556–1561. [CrossRef] [PubMed]

62. Yan, M.; Wang, L.; Zuo, H.; Zhang, Z.; Chen, W.; Mao, L.; Zhang, P. HH/GLI signalling as a new therapeutic target for patients with oral squamous cell carcinoma. *Oral Oncol.* 2011, 47, 504–509. [CrossRef] [PubMed]

63. Cavicchioli Buim, M.E.; Gurgel, C.A.; Goncalves Ramos, E.A.; Lourenco, S.V.; Soares, F.A. Activation of sonic hedgehog signaling in oral squamous cell carcinomas: A preliminary study. *Hum. Pathol.* 2011, 42, 1484–1490. [CrossRef] [PubMed]

64. Honami, T.; Shimo, T.; Okui, T.; Kurio, N.; Hassan, N.M.; Iwamoto, M.; Sasaki, A. Sonic hedgehog signaling promotes growth of oral squamous cell carcinoma cells associated with bone destruction. *Oral Oncol.* 2012, 48, 49–55. [CrossRef] [PubMed]

65. Chen, J.K.; Taipale, J.; Cooper, M.K.; Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. *Genes Dev.* 2002, 16, 2743–2748. [CrossRef] [PubMed]

66. Mozet, C.; Stoehr, M.; Dimitrova, K.; Dietz, A.; Wichmann, G. Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects. *Anticancer Res.* 2013, 33, 2415–2424. [PubMed]

67. Gupta, S.; Takebe, N.; Lorusso, P. Targeting the Hedgehog pathway in cancer. *Thr. Adv. Med. Oncol.* 2010, 2, 237–250. [CrossRef] [PubMed]

68. Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N. Engl. J. Med.* 2009, 361, 1173–1178. [CrossRef] [PubMed]

69. Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N. Engl. J. Med.* 2009, 361, 1164–1172. [CrossRef] [PubMed]

70. Scales, S.J.; de Sauvage, F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. *Trends Pharmacol. Sci.* 2009, 30, 303–312. [CrossRef] [PubMed]

71. Stanton, B.Z.; Peng, L.F. Small-molecule modulators of the Sonic Hedgehog signaling pathway. *Mol. Biosyst.* 2010, 6, 44–54. [CrossRef] [PubMed]

72. Zhang, Y.; Laterra, J.; Pomper, M.G. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. *Neoplasia* 2009, 11, 96–101. [CrossRef] [PubMed]

73. Huang, Y.C.; Chao, K.S.; Liao, H.F.; Chen, Y.J. Targeting sonic hedgehog signaling by compounds and derivatives from natural products. *Evid. Based Complement. Altern. Med.* 2013, 2013, 748857. [CrossRef] [PubMed]
74. Meulmeester, E.; Ten Dijke, P. The dynamic roles of TGF-β in cancer. *J. Pathol.* 2011, 223, 205–218. [CrossRef] [PubMed]
75. Papageorgis, P.; Stylianopoulos, T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery. *Int. J. Oncol.* 2015, 46, 933–943. [CrossRef] [PubMed]
76. Ahmed, S.; Bradshaw, A.D.; Gera, S.; Dewan, M.Z.; Xu, R. The TGF-β/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance. *J. Clin. Med.* 2017, 6, 5. [CrossRef] [PubMed]
77. Yoshida, K.; Murata, M.; Yamaguchi, T.; Matsuzaki, K. TGF-β/Smad signaling during hepatic fibro-carcinogenesis. *Int. J. Oncol.* 2014, 45, 1363–1371. [CrossRef] [PubMed]
78. Sivadas, V.P.; George, N.A.; Kattoor, J.; Kannan, S. Novel mutations and expression alterations in SMAD3/TGFBR2 genes in oral carcinoma correlate with poor prognosis. *Genes. Chromosom. Cancer* 2013, 52, 1042–1052. [CrossRef] [PubMed]
79. Chen, Y.K.; Huang, A.H.; Cheng, P.H.; Yang, S.H.; Lin, L.M. Overexpression of Smad proteins, especially Smad7, in oral epithelial dysplasias. *Clin. Oral Investig.* 2013, 17, 921–932. [CrossRef] [PubMed]
80. Chen, Y.K.; Yang, S.H.; Huang, A.H.; Hsue, S.S.; Lin, L.M. Aberrant expression in multiple components of the transforming growth factor-β1-induced Smad signaling pathway during 7,12-dimethylbenz[a]anthracene-induced hamster buccal-pouch squamous-cell carcinogenesis. *Oral Oncol.* 2011, 47, 262–267. [CrossRef] [PubMed]
81. Mangone, F.R.; Walder, F.; Maistro, S.; Pasini, F.S.; Lehn, C.N.; Carvalho, M.B.; Brentani, M.M.; Snitcovsky, I.; Federico, M.H. Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients. *Mol. Cancer* 2010, 9, 106. [CrossRef] [PubMed]
82. Park, I.; Son, H.K.; Che, Z.M.; Kim, J. A novel gain-of-function mutation of TGF-β receptor II promotes cancer progression via delayed receptor internalization in oral squamous cell carcinoma. *Cancer Lett.* 2012, 315, 161–169. [CrossRef] [PubMed]
83. Uehara, E.; Shibata, M.; Shinozuka, K.; Saito, K.; Kouzu, Y.; Koike, H.; Kasamatsu, A.; Sakamoto, Y.; Ogawara, K.; Uzawa, K.; et al. Uregulated expression of ADAM12 is associated with progression of oral squamous cell carcinoma. *Int. J. Oncol.* 2012, 40, 1414–1422. [PubMed]
84. Saito, D.; Kyakumoto, S.; Chosa, N.; Ibi, M.; Takahashi, N.; Okubo, N.; Sawada, S.; Ishisaki, A.; Kamo, M. Transforming growth factor-β1 induces epithelial-mesenchymal transition and integrin α3β1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug. *J. Biochem.* 2013, 153, 303–315. [CrossRef] [PubMed]
85. Kim, S.G.; Song, J.Y. Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides in oral squamous cell carcinoma. *Onco. Rep.* 2012, 28, 539–544. [CrossRef] [PubMed]
86. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 2004, 116, 281–297. [CrossRef] [PubMed]
87. MacDonagh, L.; Gray, S.G.; Finn, S.P.; Cuffe, S.; O’Byrne, K.J.; Barr, M.P. The emerging role of microRNAs in resistance to lung cancer treatments. *Cancer Treat. Rev.* 2015, 41, 160–169. [CrossRef] [PubMed]
88. Esquela-Kerscher, A.; Slack, F.J. Oncomirs—microRNAs with a role in cancer. *Nat. Rev. Cancer* 2006, 6, 259–269. [CrossRef] [PubMed]
89. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 2015, 4, e05005. [CrossRef] [PubMed]
90. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. *Nat. Rev. Drug Discov.* 2013, 12, 931–947. [CrossRef] [PubMed]
91. Peng, X.; Gandhi, V. ROS-activated anticancer prodrugs: A new strategy for tumor-specific damage. *Ther. Deliv.* 2012, 3, 823–833. [CrossRef] [PubMed]
92. Yeh, C.C.; Tseng, C.N.; Yang, J.I.; Huang, H.W.; Fang, Y.; Tang, J.Y.; Chang, F.R.; Chang, H.W. Antiproliferation and induction of apoptosis in Ca9-22 oral cancer cells by ethanolic extract of *Gracilaria tenuistipitata*. *Molecules* 2012, 17, 10916–10927. [CrossRef] [PubMed]
93. Yen, Y.H.; Farooqi, A.A.; Li, K.T.; Butt, G.; Tang, J.Y.; Wu, C.Y.; Cheng, Y.B.; Hou, M.F.; Chang, H.W. Methanolic extracts of *Solieria robusta* inhibits proliferation of oral cancer Ca9-22 cells via apoptosis and oxidative stress. *Molecules* 2014, 19, 18721–18732. [CrossRef] [PubMed]
94. Yen, C.Y.; Chiu, C.C.; Haung, R.W.; Yeh, C.C.; Huang, K.J.; Chang, K.F.; Hseu, Y.C.; Chang, F.R.; Chang, H.W.; Wu, Y.C. Antiproliferative effects of goniothalamin on Ca9-22 oral cancer cells through apoptosis, DNA damage and ROS induction. *Mutat. Res.* 2012, 747, 253–258. [CrossRef] [PubMed]
103. Liu, C.; Wang, Z.; Wang, Y.; Gu, W. MiR-338 suppresses the growth and metastasis of OSCC cells by targeting
102. Szklarczyk, D.; Morris, J.H.; Cook, H.; Kuhn, M.; Wyder, S.; Simonovic, M.; Santos, A.; Doncheva, N.T.;
97. Zhang, L.; Wang, H.; Li, W.; Zhong, J.; Yu, R.; Huang, X.; Tang, Z.; Wang, J.; Zhang, Y. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget 2017, 8, 3289–3303. [CrossRef] [PubMed]
95. Lee, S.Y.; Jeong, E.K.; Ju, M.K.; Jeon, H.M.; Kim, M.Y.; Kim, C.H.; Park, H.G.; Han, S.I.; Kang, H.S. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol. Cancer 2017, 16, 10. [CrossRef] [PubMed]
94. Lin, Z.; Sun, L.; Chen, W.; Liu, B.; Wang, Y.; Fan, S.; Li, Y.; Li, J. MiR-639 regulates transforming growth factor
101. Jiang, F.; Zhao, W.; Zhou, L.; Zhang, L.; Liu, Z.; Yu, D. MiR-222 regulates the cell biological behavior of oral
111. Huang, W.C.; Chan, S.H.; Jang, T.H.; Chang, J.W.; Ko, Y.C.; Yen, T.C.; Chiang, S.L.; Chiang, W.F.; Shieh, T.Y.;
109. Yang, X.; Wu, H.; Ling, T. Suppressive effect of microRNA-126 on oral squamous cell carcinoma in vitro.
104. Lin, Z.; Sun, L.; Chen, W.; Liu, B.; Wang, Y.; Fan, S.; Li, Y.; Li, J. MiR-639 regulates transforming growth factor
112. Yu, T.; Liu, K.; Wu, Y.; Fan, J.; Chen, J.; Li, C.; Yang, Q.; Wang, Z. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway. Oncogene 2014, 33, 5017–5027. [CrossRef] [PubMed]
113. Kawakita, A.; Yamamoto, S.; Yamada, S.; Naruse, T.; Takahashi, H.; Kawasaki, G.; Umeda, M. MicroRNA-21 promotes oral cancer invasion via the Wnt/β-catenin pathway by targeting DKK2. Pathol. Oncol. Res. 2014, 20, 253–261. [CrossRef] [PubMed]
114. Wilmink, G.J.; Roth, C.L.; Ibest, B.L.; Ketchum, N.; Bernhard, J.; Cerna, C.Z.; Roach, W.P. Identification of microRNAs associated with hyperthermia-induced cellular stress response. Cell Stress Chaperones 2010, 15, 1027–1038. [CrossRef] [PubMed]

115. Bernatchez, G.; Giroux, V.; Lassalle, T.; Carpentier, A.C.; Rivard, N.; Carrier, J.C. ERRαx metabolic nuclear receptor controls growth of colon cancer cells. Carcinogenesis 2013, 34, 2253–2261. [CrossRef] [PubMed]

116. Cavallini, A.; Notarnicola, M.; Giannini, R.; Montemurro, S.; Lorusso, D.; Visconti, A.; Minervini, F.; Caruso, M.G. Oestradiol receptor-related receptor α (ERαR) and oestrogen receptors (ERα and ERβ) exhibit different gene expression in human colorectal tumour progression. Eur. J. Cancer 2005, 41, 1487–1494. [CrossRef] [PubMed]

117. Nikolic, I.; Plate, K.H.; Schmidt, M.H. EGFL7 meets miRNA-126: An angiogenesis alliance. J. Angiogenes Res. 2010, 2, 9. [CrossRef] [PubMed]

118. Xiao, C.; Wang, L.; Zhu, L.; Zhang, C.; Zhou, J. Curcumin inhibits oral squamous cell carcinoma SCC-9 cells proliferation by regulating miR-9 expression. Biochem. Biophys. Res. Commun. 2014, 454, 576–580. [CrossRef] [PubMed]

119. Farooqi, A.A.; Li, K.T.; Fayyaz, S.; Chang, Y.T.; Ismail, M.; Okamoto, T.; Murakami, A.; Maehara, Y.; Kitajima, S. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J. Biol. Chem. 2014, 289, 21544–21561. [PubMed]

120. Kim, J.; Yun, M.; Kim, E.O.; Jung, D.B.; Won, G.; Kim, B.; Jung, J.H.; Kim, S.H. Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated-endoplasmic reticulum stress signalling in non-small cell lung cancers. Br. J. Pharmacol. 2016, 173, 1033–1044. [CrossRef] [PubMed]

121. Tiwary, R.; Yu, W.; Li, J.; Park, S.K.; Sanders, B.G.; Kline, K. Role of endoplasmic reticulum stress in α-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS ONE 2010, 5, e11865. [CrossRef] [PubMed]

122. Martin-Perez, R.; Niwa, M.; Lopez-Rivas, A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis 2012, 17, 349–363. [CrossRef] [PubMed]

123. Huang, Y.; Wang, Y.; Li, X.; Chen, Z.; Li, X.; Wang, H.; Ni, M.; Li, J. Molecular mechanism of ER stress-induced gene expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in macrophages. FEBs J. 2015, 282, 2361–2378. [CrossRef] [PubMed]

124. Fukuda, M.; Hamao, A.; Tanaka, A.; Kitada, M.; Suzuki, S.; Kusama, K.; Sakashita, H. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol. Rep. 2003, 10, 1113–1119. [CrossRef] [PubMed]

125. Teng, Y.; Gao, M.; Wang, J.; Kong, Q.; Hu, H.; Luo, T.; Jiang, Y. Inhibition of elf2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. Cell Death Dis. 2014, 5, e1060. [CrossRef] [PubMed]

126. Ma, Z.; Fan, C.; Yang, Y.; Di, S.; Hu, W.; Li, T.; Zhu, Y.; Han, J.; Xin, Z.; Wu, G.; et al. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation. Sci. Rep. 2016, 6, 35196. [CrossRef] [PubMed]

127. Fukuda, M.; Hamaw, A.; Tanaka, A.; Kitada, M.; Suzuki, S.; Kusama, K.; Sakashita, H. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol. Rep. 2003, 10, 1113–1119. [CrossRef] [PubMed]

128. Teng, Y.; Gao, M.; Wang, J.; Kong, Q.; Hu, H.; Luo, T.; Jiang, Y. Inhibition of elf2α dephosphorylation enhances TRAIL-induced apoptosis in hepatoma cells. Cell Death Dis. 2014, 5, e1060. [CrossRef] [PubMed]

129. Ma, Z.; Fan, C.; Yang, Y.; Di, S.; Hu, W.; Li, T.; Zhu, Y.; Han, J.; Xin, Z.; Wu, G.; et al. Thapsigargin sensitizes human esophageal cancer to TRAIL-induced apoptosis via AMPK activation. Sci. Rep. 2016, 6, 35196. [CrossRef] [PubMed]
132. Utaipan, T.; Athipornchai, A.; Suksamrarn, A.; Chunsrivorot, S.; Chunglok, W. Isomahanine induces endoplasmic reticulum stress and simultaneously triggers p38 MAPK-mediated apoptosis and autophagy in multidrug-resistant human oral squamous cell carcinoma cells. *Oncol. Rep.* 2017, 37, 1243–1252. [PubMed]

133. Su, C.H.; Kuo, C.L.; Lu, K.W.; Yu, F.S.; Ma, Y.S.; Yang, J.L.; Chu, Y.L.; Chueh, F.S.; Liu, K.C.; Chung, J.G. Fisetin-induced apoptosis of human oral cancer SCC-4 cells through reactive oxygen species production, endoplasmic reticulum stress, caspase-, and mitochondria-dependent signaling pathways. *Environ. Toxicol.* 2017, 32, 1725–1741. [CrossRef] [PubMed]

134. Zhao, Y.; Li, Y.; Wang, L.; Yang, H.; Wang, Q.; Qi, H.; Li, S.; Zhou, P.; Liang, P.; Wang, Q.; et al. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. *J Exp. Clin. Cancer Res.* 2013, 32, 10. [CrossRef] [PubMed]

135. Catto, J.W.; Alcaraz, A.; Bjartell, A.S.; De Vere White, R.; Evans, C.P.; Fussel, S.; Hamdy, F.C.; Kallioniemi, O.; Mengual, L.; Schlommm, T.; et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. *Eur. Urol.* 2011, 59, 671–681. [CrossRef] [PubMed]

136. Liu, J.; Ma, L.; Li, C.; Zhang, Y.; Yang, G.; Zhang, W. Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. *Mol. Oncol.* 2013, 7, 1043–1055. [CrossRef] [PubMed]

137. Huo, W.; Jin, N.; Fan, L.; Wang, W. MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells. *Mol. Cell. Biochem.* 2014, 388, 123–133. [CrossRef] [PubMed]

138. Yan, Y.; Zhang, F.; Fan, Q.; Li, X.; Zhou, K. Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122. *Neoplasma* 2014, 61, 672–679. [CrossRef] [PubMed]

139. Joshi, P.; Jeon, Y.J.; Lagana, A.; Middleton, J.; Secchiero, P.; Garofalo, M.; Croce, C.M. MicroRNA-148a reduces response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. *J Exp. Clin. Cancer Res.* 2013, 32, 10. [CrossRef] [PubMed]

140. Farooqi, A.A.; Yaylim, I.; Ozkan, N.E.; Zaman, F.; Halim, T.A.; Chang, H.W. Restoring TRAIL mediated signaling in ovarian cancer cells. *Arch. Immunol. Ther. Exp.* 2014, 62, 459–474. [CrossRef] [PubMed]

141. Farooqi, A.A.; De Rosa, G. TRAIL and microRNAs in the treatment of prostate cancer: Therapeutic potential and role of nanotechnology. *Appl. Microbiol. Biotechnol.* 2013, 97, 8849–8857. [CrossRef] [PubMed]

142. Luo, T.; Shao, N.; Ji, C. Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells. *Cancer Gene Ther.* 2013, 20, 33–37. [CrossRef] [PubMed]

143. Zhu, J.; Zhou, Q.; Tan, S. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer. *Cancer Lett.* 2016, 383, 154–160. [CrossRef] [PubMed]

144. Garofalo, M.; Condorelli, G.L.; Croce, C.M.; Condorelli, G. MicroRNAs as regulators of death receptors signaling. *Cell Death Differ.* 2010, 17, 200–208. [CrossRef] [PubMed]

145. Razumilava, N.; Bronk, S.F.; Smoot, R.L.; Fingas, C.D.; Werneburg, N.W.; Roberts, L.R.; Mott, J.L. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. *Hepatology* 2012, 55, 465–475. [CrossRef] [PubMed]

146. Shin, E.A.; Sohn, E.J.; Won, G.; Choi, J.U.; Jeong, M.; Kim, B.; Kim, M.J.; Kim, S.H. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. *Oncotarget* 2014, 5, 5624–5636. [CrossRef] [PubMed]

147. Dennenl, S.; Andre, J.; Alexaki, I.; Li, A.; Magnaldo, T.; ten Dijke, P.; Wang, X.J.; Verrecchia, F.; Mauviel, A. Induction of sonic hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. *Cancer Res.* 2007, 67, 6981–6986. [CrossRef] [PubMed]

148. Javelaud, D.; Pierrat, M.J.; Mauviel, A. Crosstalk between TGF-β and hedgehog signaling in cancer. *FEBS Lett.* 2012, 586, 2016–2025. [CrossRef] [PubMed]

149. Li, X.; Deng, W.; Nail, C.D.; Bailey, S.K.; Kraus, M.H.; Ruppert, J.M.; Lobo-Ruppert, S.M. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. *Oncogene* 2006, 25, 609–621. [CrossRef] [PubMed]

150. Aval, S.F.; Lotfi, H.; Sheervailou, R.; Zarghami, N. Tuning of major signaling networks (TGF-β, Wnt, Notch and Hedgehog) by miRNAs in human stem cells commitment to different lineages: Possible clinical application. *Biomed. Pharmacother.* 2017, 91, 849–860. [CrossRef] [PubMed]
152. Guo, L.; Zhang, Y.; Zhang, L.; Huang, F.; Li, J.; Wang, S. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer. *Tumour Biol.* **2016**, *37*, 115–125. [CrossRef] [PubMed]

153. Onyido, E.K.; Sweeney, E.; Nateri, A.S. Wnt-signalling pathways and microRNAs network in carcinogenesis: Experimental and bioinformatics approaches. *Mol. Cancer* **2016**, *15*, 56. [CrossRef] [PubMed]

154. Peng, Y.; Zhang, X.; Feng, X.; Fan, X.; Jin, Z. The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer. *Oncotarget* **2017**, *8*, 14089–14106. [CrossRef] [PubMed]

155. Rahmani, F.; Avan, A.; Hashemy, S.I.; Hassanian, S.M. Role of Wnt/β-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer. *J. Cell. Physiol.* **2017**. [CrossRef] [PubMed]

156. Song, J.L.; Nigam, P.; Tektas, S.S.; Selva, E. MicroRNA regulation of Wnt signaling pathways in development and disease. *Cell Signal.* **2015**, *27*, 1380–1391. [CrossRef] [PubMed]

157. Hyun, J.; Jung, Y. MicroRNAs in liver fibrosis: Focusing on the interaction with hedgehog signaling. *World J. Gastroenterol.* **2016**, *22*, 6652–6662. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).